Zenas Biopharma

Zenas Biopharma EBITDA per Employee

The EBITDA per Employee of Zenas Biopharma (ZBIO) as of Oct 27, 2026 is -1.27 M USD. In the previous year, EBITDA per Employee was -981,365.27 USD — a change of 28.98% (lower).

EBITDA per Employee

-1.27 MUSD

YoY

28.98%

Last updated:

EBITDA per Employee of Zenas Biopharma is 2025 -1.27 M USD. EBITDA per Employee of Zenas Biopharma was 2024 -981,365.27 USD. It decreases by 28.98% lower compared to the previous year.

The Zenas Biopharma EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2022
-456,281.44 USD
Jan 1, 2023
-222,437.13 USD
Jan 1, 2024
-981,365.27 USD
Jan 1, 2025
-1.27 M USD
The Zenas Biopharma EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.27 MUSD+28.98%
-981,365.27USD+341.19%
-222,437.13USD-51.25%
-456,281.44USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Zenas Biopharma Stock analysis

What does Zenas Biopharma do? Zenas Biopharma Inc generates revenue through the development and commercialization of immunology-based therapies, primarily focusing on its lead product candidate obexelimab. This bifunctional monoclonal antibody targets CD19 and FcyRIIb for treating autoimmune diseases without depleting B cells. The company also develops ZB002, an anti-TNFα monoclonal antibody, and ZB004, a CTLA-4-Ig fusion, as part of its global pipeline. Regional programs include ZB001 (VRDN-001) for IGF-1R targeting and ZB005 (DNTH103) for anti-active C1s therapy, all under the company's development and commercialization rights. The company targets patients with autoimmune diseases through its clinical-stage therapies, with obexelimab positioned as a potential franchise for multiple conditions. ZB002 and ZB004 are global programs aimed at broader market reach, while ZB001 and ZB005 are regional initiatives tailored to specific markets. Revenue streams are expected from future commercial sales of these therapies once approved and launched. Zenas Biopharma Inc develops its products internally with a focus on immunology and inflammation, leveraging its pipeline of monoclonal antibodies. The company's business model relies on advancing these candidates through clinical trials to eventual commercialization, with revenue anticipated from the sale of approved therapies to healthcare providers and patients in the target markets. Zenas Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenas Biopharma stock

EBITDA per Employee of Zenas Biopharma is -1.27 M USD in 2025.

EBITDA per Employee of Zenas Biopharma changed from -981,365.27 USD to -1.27 M USD, representing a 28.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Zenas Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Zenas Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Zenas Biopharma

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Zenas Biopharma